Gamma-glutamyl transferase-to-lymphocyte ratio as a prognostic marker in patients with hepatocellular carcinoma undergoing hepatectomy

Table 1 Correlation between gamma-glutamyl transferase-to-lymphocyte ratio and clinical and pathological characteristics of hepatocellular carcinoma

Variables	Total (n = 293)	GLR-low (n = 139)	GLR-high (n = 154)	χ2	P value
Sex				7.000	0.008a
Male	248 (84.6)	109 (78.4)	139 (90.3)
Female	45 (15.4)	30 (21.6)	15 (9.7)
Age (year)				2.731	0.10
< 60	187 (63.8)	96 (69.1)	91 (59.1)
≥ 60	106 (36.2)	43 (30.9)	63 (40.9)
BMI (kg/m2)				10.748	0.005a
< 18.5	24 (8.2)	19 (13.7)	5 (3.2)
18.5-24	203 (69.3)	89 (64.0)	114 (74.0)
> 24	66 (22.5)	31 (22.3)	35 (22.7)
Ascites				0.210	0.647
Negative	273 (93.2)	131 (94.2)	142 (92.2)
Positive	20 (6.8)	8 (5.8)	12 (7.8)
WBC (109/L)				1.629	0.202
> 10	29 (9.9)	10 (7.2)	19 (12.3)
4-10	264 (90.1)	129 (92.8)	135 (87.7)
Monocyte (109/L)				0.897	0.344
> 0.8	13 (4.4)	4 (2.9)	9 (5.8)
0.3-0.8	280 (95.6)	135 (97.1)	145 (94.2)
RDW				0.023	0.880
> 18	25 (8.5)	11 (7.9)	14 (9.1)
10-18	268 (91.5)	128 (92.1)	140 (90.9)
ALT (U/L)				1.358	0.244
> 40	106 (36.2)	45 (32.4)	61 (39.6)
≤ 40	187 (63.8)	94 (67.6)	93 (60.4)
AST (U/L)				12.848	< 0.001a
> 40	117 (39.9)	40 (28.8)	77 (50.0)
≤ 40	176 (60.1)	99 (71.2)	77 (50.0)
ALB (g/L)				4.250	0.039
< 40	47 (16.0)	59 (42.4)	85 (55.2)
≥ 40	246 (84.0)	80 (57.6)	69 (44.8)
ALP (U/L)				18.103	< 0.001a
> 150	103 (35.2)	31 (22.3)	72 (46.8)
40-150	190 (64.8)	108 (77.3)	82 (53.2)
TBIL (μmol/L)				13.794	< 0.001a
> 17.1	142 (48.5)	51 (36.7)	91 (59.1)
3.4-17.1	151 (51.5)	88 (63.3)	63 (40.9)
DBIL (μmol/L)				0.300	0.584
> 6.8	62 (21.2)	27 (19.4)	35 (22.7)
0-6.8	231 (78.8)	112 (80.6)	119 (77.3)
PT (second)				0.028	0.866
> 13	84 (28.7)	41 (29.5)	43 (27.9)
11-13	209 (71.3)	98 (70.5)	111 (72.1)
HBsAg				0.009	0.925
Positive	51 (17.4)	25 (18.0)	26 (16.9)
Negative	242 (82.6)	114 (82.0)	128 (83.1)
AFP (μg/L)				5.676	0.017a
≥ 25	178 (60.8)	74 (53.2)	104 (67.5)
< 25	115 (39.2)	65 (46.8)	50 (32.5)
Tumor count				9.902	0.002a
Single	251 (85.7)	129 (92.8)	122 (79.2)
Multiple	42 (14.3)	10 (7.2)	32 (20.8)
Tumor diameter (cm)				28.262	< 0.001a
≤ 2	57 (19.5)	40 (28.8)	17 (11.0)
> 2, ≤ 5	122 (41.6)	65 (46.8)	57 (37.0)
> 5, ≤ 10	67 (22.9)	22 (15.8)	45 (29.2)
> 10	47 (16.0)	12 (8.6)	35 (22.8)
Degree of differentiation				3.819	0.148
Low and low-medium	50 (17.1)	22 (15.8)	28 (18.2)
Medium and high-medium	222 (75.8)	111 (79.9)	111 (72.1)
High	21 (7.1)	6 (4.3)	15 (9.7)
MVI				16.516	< 0.001a
0	183 (62.5)	101 (72.7)	82 (53.3)
1	71 (24.2)	30 (21.6)	41 (26.6)
2	39 (13.3)	8 (5.7)	31 (20.1)
Child-Pugh grade
A	285 (97.3)	138 (99.3)	147 (95.5)	2.720	0.099
B	8 (2.7)	1 (0.7)	7 (4.5)
C	0 (0)	0 (0)	0 (0)
Postoperative TACE				5.064	0.024a
Yes	107 (36.5)	41 (29.5)	66 (42.9)
No	186 (63.5)	98 (70.5)	88 (57.1)
PLR				22.216	< 0.001a
Low	159 (54.3)	96 (69.1)	63 (40.9)
High	134 (45.7)	43 (30.9)	91 (59.1)
NLR				15.753	< 0.001a
Low	132 (45.1)	80 (57.6)	52 (33.8)
High	161 (54.9)	59 (42.4)	102 (66.2)

^aP < 0.05.

Data presented as n (%). AFP: α-fetoprotein; ALB: Albumin; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: Body mass index; DBIL: Direct bilirubin; GLR: Gamma-glutamyl transferase-to-lymphocyte ratio; HBsAg: Hepatitis B surface antigen; MVI: Microvascular invasion; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; PT: Prothrombin time; RDW: Red cell distribution width; TACE: Transarterial chemoembolization; TBIL: Total bilirubin.